DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.
Clinical role
Calculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
Images and patients
Mammography/DBT · Breast
Key limitation
Scanner manufacturers: Hologic/Lorad
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyMammography/DBT · Breast
Workflow roleCalculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
Required inputDICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.
Output and human actionFor each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
DM-Density is a software application intended for use with compatible full field digital mammography systems. DMDensity calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates. DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.
Calculates percent breast density per breast and a density category from full field digital mammography, output as a DICOM Structured Report or Secondary Capture for workstation or PACS viewing; adjunctive information for interpreting physicians, not a diagnostic aid.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DM-Density is a software application intended for use with compatible full field digital mammography systems. DM-Density calculates percent breast density defined as the ratio of fibroglandular tissue to total breast area estimates." … "DM-Density provides these numerical values for each breast as well as a density category to aid interpreting physicians in the assessment of breast tissue composition. DM-Density produces adjunctive information. It is not a diagnostic aid.". Read from the exact FDA decision document on 2026-11-14.
DICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DM-Density is a standalone software application that automatically analyzes “for presentation” full field digital mammograms to calculate breast tissue composition." … "DM-Density has been validated on Hologic’s Selenia Dimensions and Lorad Selenia systems.". Read from the exact FDA decision document on 2026-11-14.
For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.
Exact FDA submission
Checked 2026-09-01
Clinical output reported in the exact-submission ACR model card.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Study type: Stand-Alone Performance
Public source
Exact FDA submission
Checked 2026-09-01
Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
DM-Density regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K170540
IndependenceIndependence not established
K170540
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K170540. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM for-presentation full field digital mammograms from compatible digital mammography systems; validated on Hologic Selenia Dimensions and Lorad Selenia systems.
Scope: Exact FDA submission. Packet wording: "DM-Density is a standalone software application that automatically analyzes “for presentation” full field digital mammograms to calculate breast tissue composition." … "DM-Density has been validated on Hologic’s Selenia Dimensions and Lorad Selenia systems.". Read from the exact FDA decision document on 2026-11-14.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes DM-Density's deployment as a standalone computer, as stated in the 510(k) Submitter column of its comparison-of-characteristics table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Table 5A – Comparison of Characteristics 510(K) Submitter Predicate" … "Deployment Standalone computer Same N/A Data Throughput 600 cases per hour". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: For each breast (BI-RADS 4th Ed.): area of fibroglandular tissue (cm²), area of breast (cm²), area-based breast density (%). For each patient (BI-RADS 4th Ed.): DM-Density breast density grade and percent breast density. For each patient (BI-RADS 5th Ed.): DM-Density breast density grade. Output is delivered as a DICOM mammography Structured Report or Secondary Capture viewable on a mammography workstation or PACS, and may also be transmitted to a RIS.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes DM-Density's deployment as a standalone computer, as stated in the 510(k) Submitter column of its comparison-of-characteristics table. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Table 5A – Comparison of Characteristics 510(K) Submitter Predicate" … "Deployment Standalone computer Same N/A Data Throughput 600 cases per hour". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
The 510(k) summary states that users must be qualified medical practitioners and exercise their professional judgment when formulating diagnostic decisions and selecting appropriate treatment paths supported by breast density estimates.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
ACR AI Central provides an exact-submission model card for DM-Density; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-08Last searched
22Fields reviewed
9Source classes checked
20Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 20 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not yet reviewed - checked 2026-08-31 - Exact FDA submission
Confirm the intended care setting, patient population, and service line.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K170540 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.